Aviptadil
Also known as: RLF-100, VIP sintético, Peptídeo Intestinal Vasoativo sintético
Molecular Identifiers
Overview
Synthetic analog of vasoactive intestinal peptide (VIP), composed of 28 amino acids. Originally developed for respiratory and vascular conditions, it acts as a potent pulmonary vasodilator and anti-inflammatory agent. Extensively researched for lung protection and surfactant function regulation.
HSDAVFTDNYTRLRKQMAVKKYLNSILN His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn Half-life
~1-2 minutes (IV)
Administration Route
Intravenous or subcutaneous
Category
Specialized Research
Mechanism of Action
- Agonism of VIP VPAC1 and VPAC2 receptors
- Pulmonary and systemic vasodilation via cAMP increase
- Anti-inflammatory action in pulmonary alveoli with reduction of pro-inflammatory cytokines
- Stimulation of surfactant production by type II pneumocytes
- Inhibition of apoptosis in alveolar epithelial cells
- Modulation of the innate immune response in the lungs
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 50-150 mcg per administration (IV or subcutaneous) |
| Frequency | 1-3 times daily per protocol |
| Timing | Per clinical guidance |
| Duration | 4-8 weeks |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Hypotension
- Tachycardia
- Nausea
- Diarrhea
- Facial flushing
Presentations & Preparation
Vials of Aviptadil found in the research market:
Reconstitution
- Diluent: Bacteriostatic water or sterile saline solution
- Volume: 1-2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved — never shake
- For IV use, dilute in saline solution per protocol
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 24 hours)
- Protect from direct light
- Do not freeze after reconstitution
- Use reconstituted solution as soon as possible
Scientific Studies
Published studies on Aviptadil.
Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate
Dinsmore WW, Gingell C, Hackett G, Kell P, Savage D, Oakes R, Frentz G
The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure
Youssef JG, Lavin P, Schoenfeld DA, Lee RA, Lenhardt R, Park DJ, et al.
Related Peptides
B7-33
100-500 mcg per injection (subcutaneous) · Once daily
Bronchogen
5-10 mg per day via subcutaneous injection · Once daily
Cardiogen
5-10 mg per day subcutaneously · Once daily
Chonluten
5-10 mg per day subcutaneously · Once daily
Crystagen
5-10 mg per day via subcutaneous injection · Once daily
Dalargin
1-2 mg per injection (subcutaneous or intramuscular) · 1-2 times daily